Description
Elicvis (Apixaban) Coated Tablets 2.5 mg. №20
Composition
Active ingredient: Apixaban 2.5 mg per tablet.
Mechanism of Action
Pharmacological Properties: Apixaban is a direct factor Xa inhibitor that works by inhibiting the activity of factor Xa, a key component in the coagulation cascade. By blocking factor Xa, apixaban prevents the formation of blood clots, reducing the risk of stroke and systemic embolism.
Indications for Use
Indications: Elicvis (apixaban) is indicated for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Contraindications
Contraindications: Do not use Elicvis (apixaban) if you have a history of allergic reactions to apixaban or any other components of the product.
Side Effects
Side Effects: Common side effects of Elicvis (apixaban) may include bleeding, bruising, and gastrointestinal discomfort. Contact your healthcare provider if you experience any severe or persistent side effects.
Usage Instructions
Dosage: The usual dose of Elicvis (apixaban) is 2.5 mg twice daily. Consult your healthcare provider for the correct dosage.
Directions: Take Elicvis (apixaban) exactly as prescribed by your healthcare provider. Do not change the dose or stop taking the medication without consulting your doctor.
Benefits Compared to Analogues
Comparative Effectiveness: Compared to traditional anticoagulants like warfarin, apixaban has shown to be as effective in preventing strokes with a lower risk of major bleeding events. This makes apixaban a favorable choice for many patients with atrial fibrillation.
Suitable Patient Groups
Elicvis (apixaban) is suitable for adult patients with nonvalvular atrial fibrillation who require anticoagulant therapy. It is important to follow the dosage recommendations provided by your healthcare provider.
Storage and Packaging
Storage: Store Elicvis (apixaban) in a cool, dry place away from direct sunlight.
Packaging: Keep the tablets in the original packaging to protect them from moisture. Check the expiration date on the packaging before use.
Clinical Evidence and Effectiveness
Elicvis (apixaban) has been extensively studied in clinical trials. Research has shown that apixaban is effective in reducing the risk of stroke and systemic embolism in patients with atrial fibrillation. A study published in the New England Journal of Medicine demonstrated that apixaban was superior to warfarin in preventing stroke or systemic embolism with less bleeding in patients with atrial fibrillation.
